{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["RNA-seq", "colorectal cancer", "doxorubicin", "oxymatrine", "synergistically effect"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34305593", "DateRevised": {"Year": "2021", "Month": "07", "Day": "27"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "06", "Day": "30"}], "Language": ["eng"], "ELocationID": ["673432", "10.3389/fphar.2021.673432"], "Journal": {"ISSN": "1663-9812", "JournalIssue": {"Volume": "12", "PubDate": {"Year": "2021"}}, "Title": "Frontiers in pharmacology", "ISOAbbreviation": "Front Pharmacol"}, "ArticleTitle": "Oxymatrine Synergistically Enhances Doxorubicin Anticancer Effects in Colorectal Cancer.", "Pagination": {"StartPage": "673432", "MedlinePgn": "673432"}, "Abstract": {"AbstractText": ["The combination of chemotherapy with natural products is a common strategy to enhance anticancer effects while alleviating the dose-dependent adverse effects of cancer treatment. Oxymatrine (OMT) has been extensively reported as having anticancer activity. Doxorubicin (DOX) is a chemotherapeutic DNA-damaging agent used for the treatment of carcinoma. In this study, we investigated whether synergistic effects exist with the combination treatment with OMT and DOX using human colorectal cancer cell (CRC) lines and the potential mechanisms involved in <i>in vitro</i> and <i>in vivo</i> activities. The MTT and colony formation assay results showed that compared to either OMT or DOX monotherapy, the combination of OMT + DOX markedly inhibited the growth of HT-29 and SW620 cells. Wound healing assays showed significant inhibition of cell migration with co-treatment, supported by the change in E-cadherin and N-cadherin expressions in Western blotting. Furthermore, flow cytometry analysis revealed that OMT + DOX co-treatment enhanced cell apoptosis as a result of ROS generation, whereas NAC attenuated OMT + DOX-induced apoptosis. Similarly, the apoptosis-related proteins (cleaved caspase-3, cleaved caspase-9, and the ratio of Bax/Bcl-2) were determined by Western blotting, which showed that the expressions of these markers were notably increased in the co-treatment group. Furthermore, co-administration of a low dose of DOX and OMT inhibited xenograft tumor growth in a dose-dependent manner. TUNEL assay and Ki67 staining images indicated more apoptosis and less proliferation occurred in OMT plus DOX-treated xenograft tumors. Meanwhile, the combination strategy decreased cardiotoxicity, which is the most serious side effect of DOX. RNA sequencing was performed to explore the precise molecular alterations involved in the combination group. Among the numerous differentially expressed genes, downregulated FHL-2 and upregulated cleaved SPTAN1 were validated in both mRNA and protein levels of HT-29 and SW620 cells. These two proteins might play a pivotal role involving in OMT + DOX synergistic activity. Overall, OMT in combination with DOX presented an outstanding synergistic antitumor effect, indicating that this beneficial combination may offer a potential therapy for CRC patients."], "CopyrightInformation": "Copyright \u00a9 2021 Pan, Zhang, Zhang, Xu, Chen, Peng, Chen, Zhang and Shen."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Pan", "ForeName": "Di", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Wen", "Initials": "W"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Nenling", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Xu", "ForeName": "Yini", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Chen", "ForeName": "Yi", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Peng", "ForeName": "Jianqing", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Chen", "ForeName": "Yan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Zhang", "ForeName": "Yanyan", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "The State Key Laboratory of Functions and Applications of Medicinal Plants (The High Efficacy Application of Natural Medicinal Resources Engineering Center of Guizhou Province), Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "The Key Laboratory of Optimal Utilization of Natural Medicine Resources, School of Pharmaceutical Sciences, Guizhou Medical University, Guiyang, China."}], "LastName": "Shen", "ForeName": "Xiangchun", "Initials": "X"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Pharmacol", "NlmUniqueID": "101548923", "ISSNLinking": "1663-9812"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ackermann A., Brieger A. (2019). The Role of Nonerythroid Spectrin \u03b1II in Cancer. J. Oncol. 2019, 7079604. 10.1155/2019/7079604", "ArticleIdList": ["10.1155/2019/7079604", "PMC6521328", "31186638"]}, {"Citation": "Ackermann A., Schrecker C., Bon D., Friedrichs N., Bankov K., Wild P., et al. (2019). Downregulation of SPTAN1 Is Related to MLH1 Deficiency and Metastasis in Colorectal Cancer. PloS one 14, e0213411. 10.1371/journal.pone.0213411", "ArticleIdList": ["10.1371/journal.pone.0213411", "PMC6411122", "30856214"]}, {"Citation": "Burnett-Hartman A. N., Lee J. K., Demb J., Gupta S. (2021). An Update on the Epidemiology, Molecular Characterization, Diagnosis, and Screening Strategies for Early-Onset Colorectal Cancer. Gastroenterology 160, 1041. 10.1053/j.gastro.2020.12.068", "ArticleIdList": ["10.1053/j.gastro.2020.12.068", "PMC8273929", "33417940"]}, {"Citation": "Cao C. Y., Mok S. W., Cheng V. W., Tsui S. K. (2015). The FHL-2 Regulation in the Transcriptional Circuitry of Human Cancers. Gene 572, 1\u20137. 10.1016/j.gene.2015.07.043", "ArticleIdList": ["10.1016/j.gene.2015.07.043", "PMC5975090", "26211626"]}, {"Citation": "Chapelle N., MartelToes-Zoutendijk M., Toes-Zoutendijk E., Barkun A. N., Bardou M. (2020). Recent Advances in Clinical Practice: Colorectal Cancer Chemoprevention in the Average-Risk Population. Gut 69, 2244\u20132255. 10.1136/gutjnl-2020-320990", "ArticleIdList": ["10.1136/gutjnl-2020-320990", "PMC7677480", "32989022"]}, {"Citation": "Frank M. H., Wilson B. J., Gold J. S., Frank N. Y. (2021). Clinical Implications of Colorectal Cancer Stem Cells in the Age of Single-Cell OMICs and Targeted Therapies. Gastroenterology 160, 1947. 10.1053/j.gastro.2020.12.080", "ArticleIdList": ["10.1053/j.gastro.2020.12.080", "PMC8215897", "33617889"]}, {"Citation": "Gal\u00e1n-Arriola C., V\u00edlchez-Tschischke J. P., Lobo M., L\u00f3pez G. J., de Molina-Iracheta A., P\u00e9rez-Mart\u00ednez C., et al. (2021). Coronary Microcirculation Damage in Anthracycline Cardiotoxicity. Cardiovasc. Res. 1, cvab053. 10.1093/cvr/cvab053", "ArticleIdList": ["10.1093/cvr/cvab053", "PMC8803079", "33605403"]}, {"Citation": "Halim C. E., Xinjing S. L., Fan L., Bailey Vitarbo J., Arfuso F., Tan C. H., et al. (2019). Anti-cancer Effects of Oxymatrine Are Mediated through Multiple Molecular Mechanism(s) in Tumor Models. Pharmacol. Res. 147, 104327. 10.1016/j.phrs.2019.104327", "ArticleIdList": ["10.1016/j.phrs.2019.104327", "31283981"]}, {"Citation": "Hua G., He C., Lv X., Fan L., Wang C., Remmenga S. W., et al. (2016). The Four and a Half LIM Domains 2 (FHL2) Regulates Ovarian Granulosa Cell Tumor Progression via Controlling AKT1 Transcription. Cell Death Dis 7, e2297. 10.1038/cddis.2016.207", "ArticleIdList": ["10.1038/cddis.2016.207", "PMC4973349", "27415427"]}, {"Citation": "Jin Y., Liu J., Liu Y., Liu Y., Guo G., Yu S., et al. (2020). Oxymatrine Inhibits Renal Cell Carcinoma Progression by Suppressing \u03b2-Catenin Expression. Front. Pharmacol. 11, 808. 10.3389/fphar.2020.00808", "ArticleIdList": ["10.3389/fphar.2020.00808", "PMC7289957", "32581789"]}, {"Citation": "Lan X., Zhao J., Zhang Y., Chen Y., Liu Y., Xu F. (2020). Oxymatrine Exerts Organ- and Tissue-Protective Effects by Regulating Inflammation, Oxidative Stress, Apoptosis, and Fibrosis: From Bench to Bedside. Pharmacol. Res. 151, 104541. 10.1016/j.phrs.2019.104541", "ArticleIdList": ["10.1016/j.phrs.2019.104541", "31733326"]}, {"Citation": "Liu C., Ma X., Zhuang J., Liu L., Sun C. (2020). Cardiotoxicity of Doxorubicin-Based Cancer Treatment: What Is the Protective Cognition that Phytochemicals Provide Us? Pharmacol. Res. 160, 105062. 10.1016/j.phrs.2020.105062", "ArticleIdList": ["10.1016/j.phrs.2020.105062", "32652197"]}, {"Citation": "Liu G. W., Liu Y. H., Jiang G. S., Ren W. D. (2018). The Reversal Effect of Ginsenoside Rh2 on Drug Resistance in Human Colorectal Carcinoma Cells and its Mechanism. Hum. Cel 31, 189\u2013198. 10.1007/s13577-017-0189-3", "ArticleIdList": ["10.1007/s13577-017-0189-3", "29582366"]}, {"Citation": "Liu L., Xie D., Xie H., Huang W., Zhang J., Jin W., et al. (2019). ARHGAP10 Inhibits the Proliferation and Metastasis of CRC Cells via Blocking the Activity of RhoA/AKT Signaling Pathway. Onco Targets Ther. 12, 11507\u201311516. 10.2147/OTT.S222564", "ArticleIdList": ["10.2147/OTT.S222564", "PMC6938210", "31920339"]}, {"Citation": "Liu Y., Bi T., Dai W., Wang G., Qian L., Gao Q., et al. (2016a). Oxymatrine Synergistically Enhances the Inhibitory Effect of 5-fluorouracil on Hepatocellular Carcinoma In Vitro and In Vivo . Tumour Biol. 37, 7589\u20137597. 10.1007/s13277-015-4642-1", "ArticleIdList": ["10.1007/s13277-015-4642-1", "26687645"]}, {"Citation": "Meeran M. F. N., Al Taee H., Azimullah S., Tariq S., Adeghate E., Ojha S. (2019). \u03b2-Caryophyllene, a Natural Bicyclic Sesquiterpene Attenuates Doxorubicin-Induced Chronic Cardiotoxicity via Activation of Myocardial Cannabinoid Type-2 (CB2) Receptors in Rats. Chem. Biol. Interact 304, 158\u2013167. 10.1016/j.cbi.2019.02.028", "ArticleIdList": ["10.1016/j.cbi.2019.02.028", "30836069"]}, {"Citation": "Nair A. B., Jacob S. S. (2016). A Simple Practice Guide for Dose Conversion between Animals and Human. J. Basic Clin. Pharm. 7 (2), 27\u201331. 10.4103/0976-0105.177703", "ArticleIdList": ["10.4103/0976-0105.177703", "PMC4804402", "27057123"]}, {"Citation": "Sehgal M., Ladabaum U., Mithal A., Singh H., Desai M., Singh G. (2021). Colorectal Cancer Incidence after Colonoscopy at Ages 45-49 or 50-54 Years. Gastroenterology 160, 2018. 10.1053/j.gastro.2021.02.015", "ArticleIdList": ["10.1053/j.gastro.2021.02.015", "33577872"]}, {"Citation": "Sun J., Sun G., Cui X., Meng X., Qin M., Sun X. (2016). Myricitrin Protects against Doxorubicin-Induced Cardiotoxicity by Counteracting Oxidative Stress and Inhibiting Mitochondrial Apoptosis via ERK/P53 Pathway. Evid. Based Complement. Alternat Med. 2016, 6093783. 10.1155/2016/6093783", "ArticleIdList": ["10.1155/2016/6093783", "PMC5039279", "27703489"]}, {"Citation": "Tian C., Yang Y., Bai B., Wang S., Liu M., Sun R. C., et al. (2021). Potential of Exosomes as Diagnostic Biomarkers and Therapeutic Carriers for Doxorubicin-Induced Cardiotoxicity. Int. J. Biol. Sci. 17, 1328\u20131338. 10.7150/ijbs.58786", "ArticleIdList": ["10.7150/ijbs.58786", "PMC8040474", "33867849"]}, {"Citation": "Tian W., Yang L., Liu Y., He J., Yang L., Zhang Q., et al. (2020). Resveratrol Attenuates Doxorubicin-Induced Cardiotoxicity in Rats by Up-Regulation of Vascular Endothelial Growth Factor B. J. Nutr. Biochem. 79, 108132. 10.1016/j.jnutbio.2019.01.018", "ArticleIdList": ["10.1016/j.jnutbio.2019.01.018", "30857673"]}, {"Citation": "Verset L., Feys L., Tr\u00e9pant A. L., De Wever O., Demetter P. (2016). FHL2: a Scaffold Protein of Carcinogenesis, Tumour-Stroma Interactions and Treatment Response. Histol. Histopathol 31, 469\u2013478. 10.14670/HH-11-709", "ArticleIdList": ["10.14670/HH-11-709", "26676939"]}, {"Citation": "Wu B., Yue H., Zhou G. H., Zhu Y. Y., Wu T. H., Wen J. F., et al. (2019). Protective Effects of Oxymatrine on Homocysteine-Induced Endothelial Injury: Involvement of Mitochondria-dependent Apoptosis and Akt-eNOS-NO Signaling Pathways. Eur. J. Pharmacol. 864, 172717. 10.1016/j.ejphar.2019.172717", "ArticleIdList": ["10.1016/j.ejphar.2019.172717", "31586637"]}, {"Citation": "Yarmohammadi F., Rezaee R., Karimi G. (2021). Natural Compounds against Doxorubicin-Induced Cardiotoxicity: A Review on the Involvement of Nrf2/ARE Signaling Pathway. Phytother Res. 35, 1163\u20131175. 10.1002/ptr.6882", "ArticleIdList": ["10.1002/ptr.6882", "32985744"]}, {"Citation": "Ye J., Zou M. M., Li P., Lin X. J., Jiang Q. W., Yang Y., et al. (2018). Oxymatrine and Cisplatin Synergistically Enhance Anti-tumor Immunity of CD8+ T Cells in Non-small Cell Lung Cancer. Front. Oncol. 8, 631. 10.3389/fonc.2018.00631", "ArticleIdList": ["10.3389/fonc.2018.00631", "PMC6305450", "30619765"]}, {"Citation": "Ye M., Zhang L., Yan Y., Lin H. (2019). Punicalagin Protects H9c2 Cardiomyocytes from Doxorubicin-Induced Toxicity through Activation of Nrf2/HO-1 Signaling. Biosci. Rep. 39, BSR20190229. 10.1042/BSR20190229", "ArticleIdList": ["10.1042/BSR20190229", "PMC6522706", "31015369"]}, {"Citation": "Zhang W., Jiang B., Guo Z., Sardet C., Zou B., Lam C. S., et al. (2010). Four-and-a-half LIM Protein 2 Promotes Invasive Potential and Epithelial-Mesenchymal Transition in colon Cancer. Carcinogenesis 31, 1220\u20131229. 10.1093/carcin/bgq094", "ArticleIdList": ["10.1093/carcin/bgq094", "20460358"]}, {"Citation": "Zhang Y. Y., Yi M., Huang Y. P. (2017). Oxymatrine Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats. Cell Physiol Biochem 43, 626\u2013635. 10.1159/000480471", "ArticleIdList": ["10.1159/000480471", "28946137"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "2", "Day": "27"}, {"Year": "2021", "Month": "5", "Day": "18"}, {"Year": "2021", "Month": "7", "Day": "26", "Hour": "6", "Minute": "22"}, {"Year": "2021", "Month": "7", "Day": "27", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "27", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "6", "Day": "30"}], "PublicationStatus": "epublish", "ArticleIdList": ["34305593", "PMC8297828", "10.3389/fphar.2021.673432", "673432"]}}], "PubmedBookArticle": []}